RESUMEN
A woman was referred to adjuvant chemotherapy after radical mastectomy. Frozen gloves were used to prevent onycholysis and neurotoxicity. Because of rapid progression of the cancer she received palliative chemotherapy. Shortly after she presented with growing subungual inflammation, first suspected to be a felon, but later diagnosed as a metastasis. Acrometastasis is very rare and is often mistaken for infection. The learning point is to consider acrometastasis when treatment for felon fails in patients with a history of cancer. A possible relationship between frozen gloves and acrometastasis cannot be excluded.
Asunto(s)
Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Adulto , Neoplasias Óseas/diagnóstico por imagen , Neoplasias de la Mama/tratamiento farmacológico , Quimioterapia Adyuvante , Resultado Fatal , Femenino , Falanges de los Dedos de la Mano , Guantes Protectores/efectos adversos , HumanosRESUMEN
INTRODUCTION: 5-Hydroxytryptamine3-receptor antagonists (5-HT3-RA) are the most widely used antiemetics in oncology, and although tolerability is high, QTC prolongation has been observed in some patients. AREAS COVERED: The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron. EXPERT OPINION: Most of the studies analyze electrocardiogram (ECG) changes after 5-HT3-RA administrations in healthy, young adults, or in noncancer patients to treat postoperative nausea and vomiting (PONV). Only a few studies have addressed ECG changes in cancer patients treated for chemotherapy-induced nausea and vomiting (CINV). Investigations in cancer patients are essential, because these patients are older and have a higher incidence of comorbidity, than those usually included in clinical trials. Furthermore, polypharmacy is frequent and drug-drug interactions between chemotherapy and other QTc-prolonging drugs may influence the pharmacokinetics and pharmacodynamics of the 5-HT3-RAs. During the next 10 - 15 years a huge increase in the number of cancer patients is expected, primarily in the group of 65-plus-year old. Therefore it will be crucial to address the incidence of cardiac AEs in cancer patients with known heart disease receiving chemotherapy and a 5-HT3 RA for the prophylaxis of CINV.
Asunto(s)
Antieméticos/efectos adversos , Enfermedades Cardiovasculares/inducido químicamente , Antagonistas del Receptor de Serotonina 5-HT3/efectos adversos , Anciano , Antieméticos/uso terapéutico , Antineoplásicos/efectos adversos , Enfermedades Cardiovasculares/epidemiología , Granisetrón/efectos adversos , Granisetrón/uso terapéutico , Humanos , Isoquinolinas/efectos adversos , Isoquinolinas/uso terapéutico , Síndrome de QT Prolongado/inducido químicamente , Síndrome de QT Prolongado/epidemiología , Náusea/inducido químicamente , Náusea/prevención & control , Neoplasias/tratamiento farmacológico , Ondansetrón/efectos adversos , Ondansetrón/uso terapéutico , Palonosetrón , Quinuclidinas/efectos adversos , Quinuclidinas/uso terapéutico , Antagonistas del Receptor de Serotonina 5-HT3/uso terapéutico , Vómitos/inducido químicamente , Vómitos/prevención & controlRESUMEN
Diaphragmatic hernia is a rare complication in pregnancy which due to misdiagnosis or management delays may be life-threatening. We report a case of a woman in the third trimester of pregnancy who presented with sudden onset of severe epigastric and thoracic pain radiating to the back. Earlier in the index pregnancy, she had undergone laparoscopic antireflux surgery (ARS) for a hiatus hernia because of severe gastro-oesophageal reflux. Owing to increasing epigastric pain a CT scan was carried out which diagnosed wrap disruption with gastric herniation into the thoracic cavity and threatened incarceration. This is, to our knowledge, the first report of severe adverse outcome after ARS during pregnancy, with acute intrathoracic gastric herniation. We recommend the avoidance of ARS in pregnancy, and the need to advise women undergoing ARS of the postoperative risks if pregnancy occurs within a few years of ARS.